News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pharm-Olam International Ltd. Adds Josh Baker, Ph.D as VP Biostatistics


6/25/2012 2:09:35 PM

HOUSTON, TX, Jun. 26, 2012 – Pharm-Olam International Ltd. (POI) a multi-national full service CRO to pharmaceutical and biotech industries, is pleased to welcome Josh Baker, Ph.D. as Vice President, Biostatistics. Baker will be responsible for expanding biostatistics deliverables to be more efficient and cost effective through POI’s proven StatAdapt system.

StatAdapt system is a comprehensive and flexible technical system for identifying opportunities for the optimization of endpoints, population definitions, and selection of statistical methods (adaptive, sequential, bayesian). StatAdapt is superior to traditional methods, by offering major time and money saving through optimization of individual studies to full development plans in a regulatory-compliant format without compromising quality.

In his career Baker has provided statistical analysis for over 35 successful marketing applications for new chemical entities, including several blockbuster drugs with revenues of over $80 billon since 2001. His roles in these applications included presenting to FDA Advisory Committees, primary statistician, and statistical management.

Baker has over 25 years of experience in the pharmaceutical and CRO industry including CEO at Ockham and PPGx, Executive VP Global Operations at PPD, and Director of Biostatistics at Glaxo, Inc. His experiences encompass technical and managerial responsibilities in all aspects of clinical research, including adaptive study design, clinical trial execution, regulatory submission planning/execution and FDA/international regulatory meetings and negotiations.

“Josh joins Pharm-Olam with an established track record of successfully obtaining special protocol assessments (SPAs) from the FDA for adaptive design studies,” said John Hovre, Chief Operating Officer at POI. “His experience in reducing cost and time to market in biometrics complements our company-wide initiatives to reduce duration of studies and produce high quality data.”

Baker has a Ph.D., Statistics, from Texas A&M University.

For further information about conducting trials with Pharm-Olam please contact John Hovre, COO at john.hovre@pharm-olam.com.

About Pharm-Olam International

Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES